Cargando…
Autoimmune epilepsy due to N-methyl-d-aspartate receptor antibodies in a child: a case report
INTRODUCTION: Seizures of autoimmune etiology may occur independent of or predate syndromes of encephalitis. We report a child with “pure” autoimmune epilepsy followed up for 7 years to highlight long-term effects of this epilepsy and the importance of early initiation and appropriate escalation of...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8527639/ https://www.ncbi.nlm.nih.gov/pubmed/34666812 http://dx.doi.org/10.1186/s13256-021-03117-5 |
_version_ | 1784586108976234496 |
---|---|
author | Wanigasinghe, Jithangi Chang, Thashi |
author_facet | Wanigasinghe, Jithangi Chang, Thashi |
author_sort | Wanigasinghe, Jithangi |
collection | PubMed |
description | INTRODUCTION: Seizures of autoimmune etiology may occur independent of or predate syndromes of encephalitis. We report a child with “pure” autoimmune epilepsy followed up for 7 years to highlight long-term effects of this epilepsy and the importance of early initiation and appropriate escalation of immunosuppression to achieve a good long-term outcome. CASE PRESENTATION: A previously healthy 5-year-old Sri Lankan boy presented with acute, frequent, brief focal seizures of temporal-lobe semiology without clinical and investigatory findings suggestive of central nervous system infection, tumor, structural abnormality, or metabolic causes. His epilepsy showed poor response to increasing doses and combinations of antiseizure medications. Further investigations detected N-methyl-d-aspartate receptor antibodies in serum, but not cerebrospinal fluid. Treatment with intravenous methyl prednisolone and maintenance on mycophenolate resulted in a rapid reduction, with seizure freedom achieved within 5–6 weeks. He relapsed when immunotherapy and anti seizure medications were reduced after seizure freedom for 24 months. This, and subsequent relapses, showed poor response to modification of anti-seizure medications, but treatment with immunotherapy (methyl prednisolone and rituximab) achieved complete seizure freedom. At 7-years of follow-up, he remains free of seizure for over 3 years, and has average academic performance and satisfactory quality of life. CONCLUSIONS: Autoimmune epilepsy is a recognized independent entity. Diagnostic criteria have been suggested for its early recognition and confirmation of diagnosis. Early diagnosis and initiation of immunosuppression, with prompt escalation of treatment when necessary, remains key to good patient outcome. |
format | Online Article Text |
id | pubmed-8527639 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-85276392021-10-25 Autoimmune epilepsy due to N-methyl-d-aspartate receptor antibodies in a child: a case report Wanigasinghe, Jithangi Chang, Thashi J Med Case Rep Case Report INTRODUCTION: Seizures of autoimmune etiology may occur independent of or predate syndromes of encephalitis. We report a child with “pure” autoimmune epilepsy followed up for 7 years to highlight long-term effects of this epilepsy and the importance of early initiation and appropriate escalation of immunosuppression to achieve a good long-term outcome. CASE PRESENTATION: A previously healthy 5-year-old Sri Lankan boy presented with acute, frequent, brief focal seizures of temporal-lobe semiology without clinical and investigatory findings suggestive of central nervous system infection, tumor, structural abnormality, or metabolic causes. His epilepsy showed poor response to increasing doses and combinations of antiseizure medications. Further investigations detected N-methyl-d-aspartate receptor antibodies in serum, but not cerebrospinal fluid. Treatment with intravenous methyl prednisolone and maintenance on mycophenolate resulted in a rapid reduction, with seizure freedom achieved within 5–6 weeks. He relapsed when immunotherapy and anti seizure medications were reduced after seizure freedom for 24 months. This, and subsequent relapses, showed poor response to modification of anti-seizure medications, but treatment with immunotherapy (methyl prednisolone and rituximab) achieved complete seizure freedom. At 7-years of follow-up, he remains free of seizure for over 3 years, and has average academic performance and satisfactory quality of life. CONCLUSIONS: Autoimmune epilepsy is a recognized independent entity. Diagnostic criteria have been suggested for its early recognition and confirmation of diagnosis. Early diagnosis and initiation of immunosuppression, with prompt escalation of treatment when necessary, remains key to good patient outcome. BioMed Central 2021-10-20 /pmc/articles/PMC8527639/ /pubmed/34666812 http://dx.doi.org/10.1186/s13256-021-03117-5 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Case Report Wanigasinghe, Jithangi Chang, Thashi Autoimmune epilepsy due to N-methyl-d-aspartate receptor antibodies in a child: a case report |
title | Autoimmune epilepsy due to N-methyl-d-aspartate receptor antibodies in a child: a case report |
title_full | Autoimmune epilepsy due to N-methyl-d-aspartate receptor antibodies in a child: a case report |
title_fullStr | Autoimmune epilepsy due to N-methyl-d-aspartate receptor antibodies in a child: a case report |
title_full_unstemmed | Autoimmune epilepsy due to N-methyl-d-aspartate receptor antibodies in a child: a case report |
title_short | Autoimmune epilepsy due to N-methyl-d-aspartate receptor antibodies in a child: a case report |
title_sort | autoimmune epilepsy due to n-methyl-d-aspartate receptor antibodies in a child: a case report |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8527639/ https://www.ncbi.nlm.nih.gov/pubmed/34666812 http://dx.doi.org/10.1186/s13256-021-03117-5 |
work_keys_str_mv | AT wanigasinghejithangi autoimmuneepilepsyduetonmethyldaspartatereceptorantibodiesinachildacasereport AT changthashi autoimmuneepilepsyduetonmethyldaspartatereceptorantibodiesinachildacasereport |